AAPL News/Earnings Headlines Exciting Day

Apple, Inc. AAPL – Options Update

Yesterday morning, AAPL was among our fresh options ideas in our premarket report, as AAPL has a tendency to run into earnings, and was slated for a post-market release. That indeed was the case, and our targets, the  AAPL Weekly $375-377.50 Calls fared reasonably well.

That being said, the party is just getting started, because not only did AAPL blow Q3 earnings expectations out of the water. but the company also announced a 4-for-1 forward split planned for August. Here are the intraday gains made by our targets yesterday, which will be significantly higher once trading commences today:

AAPL Weekly $375-377.50 Calls
$375:
 10.19-15.11 (+48%)
$377.50: 8.80-13.50 (+53%)

AAPL will open at fresh all time highs, and send those contracts soaring. We’re also going to add a few other possible targets to take advantage of the current activity, with the AAPL Weekly $407.50-412.50 Calls* as well as the 08/07 $415 Calls.


More Options Review

We also had ranges of ideas in several other options chains yesterday morning and saw some truly explosive gains. Here are the ranges and total multibag profit opportunities that they provided:

QCOM Weekly $102-104 Calls
$102: 1.05-5.66 (+439%)
$103: .96-4.94 (+415%)
$104: .35-4.00 (+1043%)
_____

PYPL Weekly $190-195 Calls
$190: 2.15-5.15 (+140%)
$192.50: 1.12-3.31 (+196%)
$195: .70-1.96 (+180%)
_____

OSTK Weekly $70-75 Calls
$70:
 1.24-9.50 (+666%)
$75: .60-5.90 (+883%)

The markets in general have a tendency to run when AAPL crushes on earnings, and that could be ready to happen today, leading to added gains in one or more of these plays.
_____

More Fresh Ideas:
SPY Weekly $324-327 Calls*
FB Weekly $245-250 Calls*

*Please don’t attempt to trade options with a weekly expiration on a Friday unless you are an advanced level trader with access to disposable funds.


Extended Watchlist:
ECOR, SONN, BSGM

DECN Recap & More

Decision Diagnostics, Corp. DECN 

We began tracking DECN just under three weeks ago, back on the morning of March 19th. The stock caught our attention after announcing that it was working on a rapid-result COVID-19 test. Subsequent to that point in time, it was trading for as little as .056/share.

Yesterday, following another tag in our extended watchlist, and as an update on the company’s coronavirus test was provided (excerpt and link below), the stock reached some very impressive new highs. It’s not the first coronavirus related play we’ve scored on, and it won’t be the last.

DECN ran 216% intraday from .125 to a new high of .395. From our initially observed low from the week before last, the stock has now exhibited an upswing of 605%

Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc.  …announces today that the company has received the Pre-EUA Acknowledgement letter from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Screening Kit. This grant by the FDA is a major milestone in our GenViro!™ Covid-19 test kit development (>>View Full PR)


Johnson & Johnson JNJ – Recap

After seeing success with a number of different targets within the JNJ chain over the past week and change, we rolled our potential strike prices up to the JNJ Weekly $140-142 Calls yesterday morning.

Being one of the lead candidates for potentially developing an effective COVID-19 vaccine, it puts JNJ in a somewhat unique position, as experts have repeatedly stated that the world cannot begin to fully recover until a viable vaccine is being widely administered sometime next year.

Our move to the $140-142 Calls proved prudent yesterday, as early activity provided the following intraday opportunities: 

JNJ Weekly $140-142 Calls
$140: .89-2.88 (+224%)
$141: .62-2.31 (+273%)
$142: .43-1.67 (+288%)
_____

Fresh Ideas:
LEVI 04/17 $12-13 Calls
SGH 04/17 $22.50-25 Calls 


Extended  Watchlist:
BIEI, MBRX PINS, BNGO, SONN, EFC, NYMT